Biohaven Ltd
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
BHVN$15.23+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders' Equity
(Amounts in thousands, except share amounts)
| Common Shares | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Net Investment from Former Parent | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive (Loss) Income | Total Shareholders' Equity | |
| Balances as of December 31, 2021 | — | $— | $34,691 | $— | $— | $— | $34,691 |
| Net loss | — | — | (479,155) | — | (91,124) | — | (570,279) |
| Net transfers from Former Parent, including separation related adjustments | — | — | 776,630 | — | — | — | 776,630 |
| Issuance of common shares in connection with the Separation and reclassification of Net investment from Former Parent | 39,375,944 | 332,166 | (332,166) | — | — | — | — |
| Issuance of common shares, net of offering costs | 28,750,000 | 282,804 | — | — | — | — | 282,804 |
| Issuance of common shares under 2022 Equity Incentive Plan | 64,535 | 772 | — | (321) | — | — | 451 |
| Non-cash share-based compensation expense | — | — | — | 14,189 | — | — | 14,189 |
| Other comprehensive income | — | — | — | — | — | 284 | 284 |
| Balances as of December 31, 2022 | 68,190,479 | 615,742 | — | 13,869 | (91,124) | 284 | 538,771 |
| Net loss | — | — | — | — | (408,168) | — | (408,168) |
| Issuance of common shares, net of offering costs | 11,761,363 | 242,425 | — | — | — | — | 242,425 |
| Issuance of common shares as payment for license agreement | 721,136 | 21,814 | — | — | — | — | 21,814 |
| Issuance of common shares under 2022 Equity Incentive Plan and employee share purchase plan | 442,745 | 7,547 | — | (2,852) | — | — | 4,695 |
| Non-cash share-based compensation expense | — | — | — | 28,787 | — | — | 28,787 |
| Other comprehensive loss | — | — | — | — | — | (349) | (349) |
| Balances as of December 31, 2023 | 81,115,723 | 887,528 | — | 39,804 | (499,292) | (65) | 427,975 |
| Net loss | — | — | — | — | (846,422) | — | (846,422) |
| Issuance of common shares, net of offering costs | 16,752,439 | 664,015 | — | — | — | — | 664,015 |
| Issuance of common shares as payment for IPR&D asset | 253,838 | 10,811 | — | — | — | — | 10,811 |
| Issuance of common shares as payment under license and other agreements | 1,970,261 | 71,627 | — | — | — | — | 71,627 |
| Obligation to issue common shares as payment under license and other agreements | — | — | — | 8,554 | — | — | 8,554 |
| Issuance of common shares under 2022 Equity Incentive Plan and 2022 Employee Share Purchase Plan | 1,129,728 | 22,721 | — | (11,292) | — | — | 11,429 |
| Issuance of warrant as payment under license agreement | — | — | — | 3,340 | — | — | 3,340 |
| Non-cash share-based compensation expense | — | — | — | 71,963 | — | — | 71,963 |
| Other comprehensive income | — | — | — | — | — | 144 | 144 |
| Balances as of December 31, 2024 | 101,221,989 | $1,656,702 | $— | $112,369 | $(1,345,714) | $79 | $423,436 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.